Performance in Initiating - Q3

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	Date of First Patient Recruited	Duration between VRA and First Patient	Benchmark Met	Comments	Reasons for delay correspond to:
11/LO/0185	PROMIS Evaluation of Multi-Parametric Magnetic Resonance Imaging In The Diagnosis and Characterisation of Prostate Cancer	30/06/2014	07/07/2014	02/10/2014	94	No	Delay in Radiology. FP	Sponsor
11/EE/0347	ECST-2 The 2nd European Carotid Surgery Trial	12/04/2014	15/04/2014			No	PI left the Trust. FP	NHS Provider
13/LO/1686	ECLIPSE: Fovista™ and Lucentis® compared to Lucentis® alone in patients with AMD (Ophthotech) A Phase 3 randomised, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.	28/05/2014	29/05/2014	01/09/2014	96	No	Delay in provision of Pharmacy information by Sponsor. FP	Sponsor

14/EM/0001	TREND (CRFB002A2411) A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration	22/04/2014	24/04/2014	02/06/2014	41	Yes	FP	Neither
13/LO/0733	NCRN544 ADAPT AGS-003 + SOC in advanced RCC	18/08/2014	22/08/2014			No	Difficult to recruit to. FP	Neither
13/NE/0197	RDP Randomized trial of wide-field guided PRP for diabetic macular oedema (DMO) treated with Ranibizumab. (Ranibizumab for DMO PRP trial (RDP trial))	22/07/2014	29/12/2014			No	Sponsor delay in returning the contract. FP	Sponsor
13/WM/0419	MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years and over	18/08/2014	30/09/2014	24/10/2014	67	Yes	FP	Neither
13/WM/0491	PROTEUS Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS)	26/03/2014	02/04/2014	31/07/2014	127	No	Poor recruiter nationally. Sponsor has extended the study on this basis. FP	Neither

13/EM/0343	COMPLETE A randomised, comparative effectiveness study of complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary interventions for ST-segment elevation myocardial infarction.	26/09/2014	30/09/2014	06/11/2014	41	Yes	FP	Neither
13/LO/0145	CLEOPATRA A multicentre phase III randomised controlled single masked clinical trial to test the clinical efficacy of Light Masks at preventing dark adaptation in the treatment of early diabetic macular oedema	16/04/2014	28/04/2014	10/07/2014	85	No	Delay in administration of certification by Sponsor. FP	Sponsor
14/SC/0100	JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With JETREA® for Vitreomacular Traction	06/05/2014	14/05/2014	03/07/2014	58	Yes	FP	Neither
13/EE/0241	CCRN 2278 - SIGNATURE Secukinumab in patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFa antagonists: A clinical trial evaluating treatment results (SIGNATURE Study CAIN457AGB01)	26/06/2014	11/07/2014	26/08/2014	61	Yes	FP	Neither
13/YH/0066	Pressure-2 Pressure Relieving Support Surfaces: A Randomised Evaluation 2	18/08/2014	01/09/2014	07/10/2014	50	Yes	FP	Neither
13/EM/0239	RESPITE Remifentanil intravenous patient controlled analgesia (PCA) versus intramuscular pethidine for pain relief in labour: a randomised controlled trial	10/07/2014	15/07/2014	04/12/2014	147	No	Difficult to recruit to. FP	Neither

14/NW/0130	RESPONSE (NT100) "A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)."	10/07/2014	11/07/2014	17/09/2014	69	Yes	FP	Neither
14/SC/0262	SAFARI A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravitreal aflibercept to ranibizumab 05. mg : the SAFARI study.	04/09/2014	11/09/2014	08/12/2014	95	No	FP	Neither
13/WM/0419	Mammographic surveillance in breast cancer patients aged 50 years and over	10/06/2014	18/06/2014	04/08/2014	55	Yes	HWP	Neither
13/EM/0266	Phase 11 randomised placebo controlled multicentre feasibility study of low dose (metronomic) cyclophosphamide with and without nintedanib (BIBF 1120) in advanced ovarian cancer	09/08/2014	18/08/2014	24/09/2014	46	Yes	HWP	Neither
12/LO/1158	Bevacizumab and combination chemotherapy in rectal cancer until surgery : a phase 11 mutilcentre open-label, randomised study of neoadjuvant chemotherapy and bevanizumab in patients with MRI defined high-risk cancer of the rectum	20/03/2014	07/04/2014	26/06/2014	98	No	Difficult to recruit to. HWP	Neither
14/LO/0203	CLARITY: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy	06/10/2014	16/10/2014	04/12/2014	59	Yes	FP	Neither

13/LO/0981	The SCIN (Skin Care intervention in Nurses) Trial	30/12/2014	31/12/2014			Within 70 days	FP	
12/NW0361	A study of Standard and New Antiepileptic Drugs – SANADII	21/11/2014	24/11/2014	13/01/2015	53	yes	FP	Neither
14/EE/1001	A 6 month, prospective, randomised, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease followed by a 6-month open-label extension	25/11/2014	15/12/2014			Within 70 days	HWP	